Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Sildenafil
    • 1.4.3 Tadalafil
    • 1.4.4 Avanafil
    • 1.4.5 Vardenafil
  • 1.5 Market by Application
    • 1.5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Retail Pharmacy
    • 1.5.4 Online Pharmacies
    • 1.5.5 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Phosphodiesterase Type 5 (PDE5) Inhibitor Industry
      • 1.6.1.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Phosphodiesterase Type 5 (PDE5) Inhibitor Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Phosphodiesterase Type 5 (PDE5) Inhibitor Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2015-2026)
  • 2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions
    • 2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Share by Regions (2015-2020)
    • 2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Phosphodiesterase Type 5 (PDE5) Inhibitor Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Market Size
    • 3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2015-2020)
    • 3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio
    • 3.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2019
  • 3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
  • 3.4 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
  • 3.5 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2015-2020)
  • 4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2021-2026)

5 Phosphodiesterase Type 5 (PDE5) Inhibitor Breakdown Data by Application (2015-2026)

  • 5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)
  • 5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in North America (2019-2020)
  • 6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Europe (2019-2020)
  • 7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

8 China

  • 8.1 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in China (2019-2020)
  • 8.3 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 8.4 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Japan (2019-2020)
  • 9.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 9.4 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

11 India

  • 11.1 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in India (2019-2020)
  • 11.3 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 11.4 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
  • 12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
  • 12.4 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Eli Lilly
    • 13.1.1 Eli Lilly Company Details
    • 13.1.2 Eli Lilly Business Overview and Its Total Revenue
    • 13.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020))
    • 13.1.5 Eli Lilly Recent Development
  • 13.2 Pfizer
    • 13.2.1 Pfizer Company Details
    • 13.2.2 Pfizer Business Overview and Its Total Revenue
    • 13.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.2.5 Pfizer Recent Development
  • 13.3 Bayer
    • 13.3.1 Bayer Company Details
    • 13.3.2 Bayer Business Overview and Its Total Revenue
    • 13.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.3.5 Bayer Recent Development
  • 13.4 Novartis AG
    • 13.4.1 Novartis AG Company Details
    • 13.4.2 Novartis AG Business Overview and Its Total Revenue
    • 13.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.4.5 Novartis AG Recent Development
  • 13.5 Merck
    • 13.5.1 Merck Company Details
    • 13.5.2 Merck Business Overview and Its Total Revenue
    • 13.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.5.5 Merck Recent Development
  • 13.6 GlaxoSmithKline plc
    • 13.6.1 GlaxoSmithKline plc Company Details
    • 13.6.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
    • 13.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.6.5 GlaxoSmithKline plc Recent Development
  • 13.7 Roche
    • 13.7.1 Roche Company Details
    • 13.7.2 Roche Business Overview and Its Total Revenue
    • 13.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.7.5 Roche Recent Development
  • 13.8 AstraZeneca
    • 13.8.1 AstraZeneca Company Details
    • 13.8.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.8.5 AstraZeneca Recent Development
  • 13.9 BaiYunShan General Factory
    • 13.9.1 BaiYunShan General Factory Company Details
    • 13.9.2 BaiYunShan General Factory Business Overview and Its Total Revenue
    • 13.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.9.5 BaiYunShan General Factory Recent Development
  • 13.10 SK Chemicals
    • 13.10.1 SK Chemicals Company Details
    • 13.10.2 SK Chemicals Business Overview and Its Total Revenue
    • 13.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 13.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 13.10.5 SK Chemicals Recent Development
  • 13.11 Teva Pharma
    • 10.11.1 Teva Pharma Company Details
    • 10.11.2 Teva Pharma Business Overview and Its Total Revenue
    • 10.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 10.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 10.11.5 Teva Pharma Recent Development
  • 13.12 Dong-A ST
    • 10.12.1 Dong-A ST Company Details
    • 10.12.2 Dong-A ST Business Overview and Its Total Revenue
    • 10.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 10.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 10.12.5 Dong-A ST Recent Development
  • 13.13 Metuchen Pharma
    • 10.13.1 Metuchen Pharma Company Details
    • 10.13.2 Metuchen Pharma Business Overview and Its Total Revenue
    • 10.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 10.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 10.13.5 Metuchen Pharma Recent Development
  • 13.14 Seoul Pharma
    • 10.14.1 Seoul Pharma Company Details
    • 10.14.2 Seoul Pharma Business Overview and Its Total Revenue
    • 10.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 10.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 10.14.5 Seoul Pharma Recent Development
  • 13.15 Vectura Group
    • 10.15.1 Vectura Group Company Details
    • 10.15.2 Vectura Group Business Overview and Its Total Revenue
    • 10.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
    • 10.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
    • 10.15.5 Vectura Group Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Eli Lilly
    Pfizer
    Bayer
    Novartis AG
    Merck
    GlaxoSmithKline plc
    Roche
    AstraZeneca
    BaiYunShan General Factory
    SK Chemicals
    Teva Pharma
    Dong-A ST
    Metuchen Pharma
    Seoul Pharma
    Vectura Group

    Market segment by Type, the product can be split into
    Sildenafil
    Tadalafil
    Avanafil
    Vardenafil
    Market segment by Application, split into
    Hospital
    Retail Pharmacy
    Online Pharmacies
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players.
    To present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Phosphodiesterase Type 5 (PDE5) Inhibitor are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now